

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

STADDON *et al.*

Appl. No.: (To be assigned)

Filed: (Herewith)

For: **Use of Vascular Endothelial
Growth Factor (VEGF)**

Art Unit: (To be assigned)

Examiner: (To be assigned)

Atty. Docket: 0623.1090001/EKS/BJD

Preliminary Amendment

Commissioner for Patents
Washington, D.C. 20231

Sir:

In advance of prosecution in the above identified matter, Applicants seek entry of the following amendments. This Preliminary Amendment is provided in the following format:

(A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;

(B) Starting on a separate page, appropriate remarks. *See* 37 C.F.R. § 1.121 and MPEP § 714; and

(C) Starting on a separate page, a marked-up version entitled: “Version with markings to show changes made.”

Please amend the application as follows:

In the Specification:

Please amend the specification as follows:

Please delete page 1 of the specification and replace it with the substitute page 1 that is appended hereto.

In the specification at page 3, prior to the first line of the paragraph appearing at lines 1-10, please insert the following header for this paragraph:

BRIEF SUMMARY OF THE INVENTION

In the specification at page 5, prior to the first line of the paragraph appearing at lines 4-25, please insert the following header for this paragraph:

DETAILED DESCRIPTION OF THE INVENTION

In the specification at page 7, please delete the header appearing at line 5 and substitute therefor the following header:

BRIEF SUMMARY OF THE DRAWINGS

In the specification at page 8, please delete the paragraph appearing at lines 9-19 and substitute therefor the following paragraph:

EXAMPLES

Methods

Chemicals and Reagents

VEGF₁₆₅ was from PeproTech. Placenta growth factor (PlGF) was from R & D Systems. Phorbol-12,13-dibutyrate (PDB) was from Calbiochem-Novabiochem. Histamine was from Sigma Chemical Co. SU5416 was prepared by Tsukuba Research Laboratories, Eisai Co., Tsukuba, Japan. Collagen (Vitrogen 100) was obtained from Imperial Laboratories (Europe). [³²P]Phosphate (10 mCi/ml, carrier free) was from ICN-Flow Laboratories. *Staphylococcus aureus* strain V8 protease (P-6306) was from Sigma.

In the Claims:

At page 22 and before claim 1, please delete the header appearing at line 1 and substitute therefor the following header:

WHAT IS CLAIMED IS:

Remarks

By the foregoing amendments, Applicants have amended the international application to provide the priority information as required by 37 C.F.R. § 1.78, to place the specification and claims into proper format for U.S. practice, and to insert the abstract (which contains the same text as that appearing on the face page of the international application as published) into the appropriate

location in the specification. Hence, no new matter has been added by the foregoing amendments, and entry and consideration of the same are respectfully requested.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Entry of the foregoing amendments and early consideration of the present application are earnestly solicited.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

Date: June 11, 2001

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005
(202) 371-2600

Version with markings to show changes made

In the Specification:

In the specification at page 1, after the title, please insert the following:

-- CROSS REFERENCE TO RELATED APPLICATION

The present application is a continuation of International Application No. PCT/GB99/04162, filed internationally on December 10, 1999, which was published in the English language under PCT Article 21(2) as WO 00/36421, the contents of which are entirely incorporated herein by reference.

BACKGROUND OF THE INVENTION

Field of the Invention --;

and at line 7, prior to the second full paragraph, please insert -- *Related Art* --.

In the specification at page 3, prior to line 1, please insert -- BRIEF SUMMARY OF THE INVENTION --.

In the specification at page 5, line 3, please insert -- DETAILED DESCRIPTION OF THE INVENTION --.

In the specification at page 7, line 5, please delete "Figures" and insert therefor -- BRIEF SUMMARY OF THE DRAWINGS --.

In the specification at page 8, line 8 (prior to "Methods"), please insert -- EXAMPLES --.

In the specification at page 22, line 1, please delete "CLAIMS" and insert therefor -- WHAT IS CLAIMED IS: --.